Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting

Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the meeting

RICHLAND, Wash & CORALVILLE, IOWA, June 16, 2023 (GLOBE NEWSWIRE) --   Perspective Therapeutics, Inc.  (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that the growing body of information regarding Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the 2023 American Brachytherapy Society (ABS) Annual Meeting to be held in Vancouver, British Columbia, Canada from June 21-24, 2023.

“We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer. He added, “We’re also excited to note that the American Brachytherapy Society is including a session entitled, ‘Implementation of Radiopharmaceuticals in the Radiation Oncology Clinic’. With our focus on alpha-particle radiopharmaceuticals and Cesium-131 brachytherapy we’re closely aligned with ABS’s interests.”

Perspective Therapeutics’ ABS Presentations
Presentation #1
Title: “Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data”
Session: Prostate Proffered Papers
Date/Time: Thursday, June 22 at 9:20 AM PT
Presenter: Ryan P. Smith, MD, Department of Radiation Oncology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA
Authors: Mohammed A. Mohammed, MD, Ronald M. Benoit, Sushil Beriwal, MD, and Ryan P. Smith, MD

The authors of presentation 1 noted that Cesium-131 LDR brachytherapy provided excellent disease-free survival rates at 5 and 10 years, comparable with recently published Stereotactic Body Radiation Therapy (SBRT) outcomes. It was noted that 47% of the brachytherapy patients had intermediate risk disease as compared to all low risk patients in the SBRT data. Cesium-131 patients’ quality of life data was very comparable to the SBRT data as well.